Differentiating between the 3 available options can help identify which is best for individual patients.
Youn Chu, PharmD, RPh
Advertisement
Articles by Youn Chu, PharmD, RPh
Advertisement
Latest Updated Articles
Advertisement
Advertisement
Trending on Pharmacy Times
1
Five-Year NATALEE Data Show Ribociclib Improves Outcomes in High-Risk HR+/HER2– Early Breast Cancer
2
Abemaciclib Provides Long-Term Survival Benefit in High-Risk Early Breast Cancer
3
Durvalumab Plus Chemotherapy Sets New Standard in Resectable Gastric and GEJ Cancer
4
TAR-200 Intravesical System Demonstrates Sustained Bladder Exposure in BCG-Unresponsive NMIBC
5
